This study group aimed to revise the 2017 international consensus guidelines for the
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …

The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are
lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of …

International experts met to discuss recent advances and to revise the 2004
recommendations for assessing and reporting precursor lesions to invasive carcinomas of …

Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that
include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic …

Background & Aims Currently, most patients with branch duct intraductal papillary mucinous
neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with …

Background Intraductal papillary mucinous neoplasms (IPMNs) are a cystic precursor to
pancreatic cancer. IPMNs deemed clinically to be at high-risk for malignant progression are …

Background & Aims Intraductal papillary mucinous neoplasms (IPMNs) are regarded as
precursors of pancreatic ductal adenocarcinomas (PDAs), but little is known about the …

Backgrounds & Aims Most guidelines for management of patients with intraductal papillary
mucinous neoplasms (IPMN) vary in proposed surveillance intervals and durations—these …

Objectives: This study evaluated individual risks of malignancy and proposed a nomogram
for predicting malignancy of branch duct type intraductal papillary mucinous neoplasms (BD …